Skip to main content

Wild new ‘Trojan horse’ nanoparticle clears your arteries by gobbling up plaque

A hungry nanoparticle that enters your body and eats away at your insides sounds like a nightmare straight out of a Michael Crichton novel. In fact, it could be a future defense against heart attacks, strokes, and potentially other fatal diseases — as strange as that might initially sound.

Recommended Videos

Developed by scientists at Michigan State and Stanford universities, the innovative new “Trojan Horse” nanoparticle works by munching away portions of the plaques responsible for heart attacks. In a proof-of-concept demonstration, the researchers recently showed that their specially developed nanoparticle is able to accurately home in on atherosclerotic plaque, which is responsible for atherosclerosis, one of the leading causes of death in the United States.

“What the nanotherapy does is it enters inflammatory monocytes [a type of white blood cell] in the blood, and carries them into the plaque — hence the ‘Trojan Horse’ label — where they become macrophages, and stimulatesthose and other macrophages in plaque to devour cellular debris,” Bryan Smith, associate professor of biomedical engineering at MSU, told Digital Trends. “This ‘taking out the trash’ attribute stabilizes the plaque with minimal side effects.”

Other applications?

Nanoparticles that can fight heart attacks already sound potentially revolutionary. But Smith believes they could be used for other applications as well.

“One might ask: Can it treat cancer?” he said. “We think so. However, such other diseases require more speculation. This strategy improves on existing treatments because of its selectivity. The nanoparticle is exquisitely selective toward inflammatory monocytes and macrophages, which allows it to decrease side effects that may be associated with other treatments.”

The work has yet to progress to human trials. So far, the researchers have proven efficacy in a culture dish and in two types of mice that have developed atherosclerosis. They next plan to test large animal models and human tissues, as well as look at how their nanotherapy measures up to other available treatments. They’re also exploring how the nanoparticles could potentially be used as diagnostic imaging tools, highlighting particular cells.

A paper describing the work, titled “Pro-efferocytic nanoparticles are specifically taken up by lesional macrophages and prevent atherosclerosis,” was recently published in the journal Nature Nanotechnology.

Luke Dormehl
Former Digital Trends Contributor
I'm a UK-based tech writer covering Cool Tech at Digital Trends. I've also written for Fast Company, Wired, the Guardian…
Range Rover’s first electric SUV has 48,000 pre-orders
Land Rover Range Rover Velar SVAutobiography Dynamic Edition

Range Rover, the brand made famous for its British-styled, luxury, all-terrain SUVs, is keen to show it means business about going electric.

And, according to the most recent investor presentation by parent company JLR, that’s all because Range Rover fans are showing the way. Not only was demand for Range Rover’s hybrid vehicles up 29% in the last six months, but customers are buying hybrids “as a stepping stone towards battery electric vehicles,” the company says.

Read more
BYD’s cheap EVs might remain out of Canada too
BYD Han

With Chinese-made electric vehicles facing stiff tariffs in both Europe and America, a stirring question for EV drivers has started to arise: Can the race to make EVs more affordable continue if the world leader is kept out of the race?

China’s BYD, recognized as a global leader in terms of affordability, had to backtrack on plans to reach the U.S. market after the Biden administration in May imposed 100% tariffs on EVs made in China.

Read more
Tesla posts exaggerate self-driving capacity, safety regulators say
Beta of Tesla's FSD in a car.

The National Highway Traffic Safety Administration (NHTSA) is concerned that Tesla’s use of social media and its website makes false promises about the automaker’s full-self driving (FSD) software.
The warning dates back from May, but was made public in an email to Tesla released on November 8.
The NHTSA opened an investigation in October into 2.4 million Tesla vehicles equipped with the FSD software, following three reported collisions and a fatal crash. The investigation centers on FSD’s ability to perform in “relatively common” reduced visibility conditions, such as sun glare, fog, and airborne dust.
In these instances, it appears that “the driver may not be aware that he or she is responsible” to make appropriate operational selections, or “fully understand” the nuances of the system, NHTSA said.
Meanwhile, “Tesla’s X (Twitter) account has reposted or endorsed postings that exhibit disengaged driver behavior,” Gregory Magno, the NHTSA’s vehicle defects chief investigator, wrote to Tesla in an email.
The postings, which included reposted YouTube videos, may encourage viewers to see FSD-supervised as a “Robotaxi” instead of a partially automated, driver-assist system that requires “persistent attention and intermittent intervention by the driver,” Magno said.
In one of a number of Tesla posts on X, the social media platform owned by Tesla CEO Elon Musk, a driver was seen using FSD to reach a hospital while undergoing a heart attack. In another post, a driver said he had used FSD for a 50-minute ride home. Meanwhile, third-party comments on the posts promoted the advantages of using FSD while under the influence of alcohol or when tired, NHTSA said.
Tesla’s official website also promotes conflicting messaging on the capabilities of the FSD software, the regulator said.
NHTSA has requested that Tesla revisit its communications to ensure its messaging remains consistent with FSD’s approved instructions, namely that the software provides only a driver assist/support system requiring drivers to remain vigilant and maintain constant readiness to intervene in driving.
Tesla last month unveiled the Cybercab, an autonomous-driving EV with no steering wheel or pedals. The vehicle has been promoted as a robotaxi, a self-driving vehicle operated as part of a ride-paying service, such as the one already offered by Alphabet-owned Waymo.
But Tesla’s self-driving technology has remained under the scrutiny of regulators. FSD relies on multiple onboard cameras to feed machine-learning models that, in turn, help the car make decisions based on what it sees.
Meanwhile, Waymo’s technology relies on premapped roads, sensors, cameras, radar, and lidar (a laser-light radar), which might be very costly, but has met the approval of safety regulators.

Read more